Wilson J. Liao

MD

Dermatologist
Clinical center director, researcher of genetics and immunity

Dr. Wilson Liao specializes in caring for patients with psoriasis and other skin disorders that may respond to phototherapy (exposure to ultraviolet light).

Liao is interested in bringing cutting-edge research technologies into patient care in the clinic, a field called translational medicine. He is involved in a number of research studies on new therapies for psoriasis and skin cancer, and welcomes patient inquiries on study participation.

Liao earned his medical degree at Harvard Medical School. He completed both his residency and fellowship in dermatology at UCSF.

  • Education

    Harvard Medical School, 2003

  • Residencies

    UCSF, Dermatology, 2007

  • Fellowships

    UCSF, Dermatology, 2007

  • Board Certifications

    Dermatology, American Board of Dermatology

  • Academic Title

    Professor

  • Languages

    German

Let’s work together to cure skin diseases. If we can imagine it, we can achieve it.

Conditions I specialize in

  • Eczema

Where I see patients (2)

    My reviews

    4.7

    Overall Experience
    81 Ratings
    About our process
    Jun 11, 2023
    Spot on.
    Apr 28, 2023
    Dr. Liao listens is empathetic and smart.
    Mar 05, 2023
    I wish we had more time to talk but I was also running late for another meeting as well.
    Jan 21, 2023
    Dr. Liao and his team are the best!
    Jul 22, 2022
    He may be the smartest guy in the world but his bedside manner is very lacking and his punctuality is worse.
    May 19, 2022
    Everything is great.
    Apr 27, 2022
    Everything is great.
    Mar 04, 2022
    Experience is good.
    Mar 04, 2022
    The woman physician in training was amazing!
    Feb 11, 2022
    Never saw care provider. Left after waiting one hour
    Feb 09, 2022
    Dr Liao is a very caring and tuned-in physician. I am so glad to have him be my physician for psoriasis.
    Oct 01, 2021
    Patient care good

    Selected research

    Decorative Caduceus

    Guselkumab Immunogenetics

    Mean change from baseline in percent of lesional CD4+ T effector cells producing IL-17

    Recruiting

    Decorative Caduceus

    Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

    Percentage change from pre-treatment baseline of CD4+ T effector cells expressing IL-4 at weeks 2, 4, 12 in dupilumab-treated patients.

    Recruiting

    Decorative Caduceus

    Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

    Patient eczema area and severity index (EASI) will be measured. It is a tool for measuring the amount and severity of eczema a patient has on his or her body, scale is 0-72, 0 means clear and 72 means severe eczema

    Recruiting

    Contact me

    Share